Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Henry Krum et al.|The Lancet|2017Cited by 1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881
Moderated Posters session IV: Viability and recovery of systolic function. The echo approach * Friday 10 December 2010, 15:30-16:30Håvard Dalen, Marija Petrović, Anders Thorstensen et al.|European Journal of Echocardiography|2010Cited by 23